Integrated Investment Consultants LLC Acquires 10,087 Shares of Merck & Co., Inc. $MRK

Posted by Francis Steltz on Jun 20th, 2026

Integrated Investment Consultants LLC raised its holdings in Merck & Co., Inc. (NYSE:MRK – Free Report) by 53.9% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 28,816 shares of the company’s stock after buying an additional 10,087 shares during the period. Integrated Investment Consultants LLC’s holdings in Merck & Co., Inc. were worth $3,033,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Norges Bank bought a new position in shares of Merck & Co., Inc. in the 4th quarter valued at about $3,997,933,000. Wellington Management Group LLP boosted its position in Merck & Co., Inc. by 14.8% during the fourth quarter. Wellington Management Group LLP now owns 86,435,458 shares of the company’s stock valued at $9,098,196,000 after purchasing an additional 11,156,354 shares during the last quarter. DLD Asset Management LP boosted its position in Merck & Co., Inc. by 30.1% during the third quarter. DLD Asset Management LP now owns 47,500,000 shares of the company’s stock valued at $3,986,675,000 after purchasing an additional 11,000,000 shares during the last quarter. Cardano Risk Management B.V. bought a new position in Merck & Co., Inc. in the fourth quarter valued at approximately $1,012,530,000. Finally, Jennison Associates LLC bought a new position in Merck & Co., Inc. in the fourth quarter valued at approximately $585,192,000. 76.07% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently issued reports on the company. Barclays began coverage on Merck & Co., Inc. in a research note on Friday, February 20th. They set an “overweight” rating and a $140.00 price objective on the stock. UBS Group boosted their target price on shares of Merck & Co., Inc. from $130.00 to $145.00 and gave the stock a “buy” rating in a report on Monday, April 13th. JPMorgan Chase & Co. upped their price target on shares of Merck & Co., Inc. from $125.00 to $135.00 and gave the stock an “overweight” rating in a research report on Monday, April 6th. Weiss Ratings cut shares of Merck & Co., Inc. from a “hold (c+)” rating to a “hold (c)” rating in a research note on Friday, May 15th. Finally, Royal Bank Of Canada reiterated an “outperform” rating and issued a $142.00 price target on shares of Merck & Co., Inc. in a research note on Monday, March 30th. One equities research analyst has rated the stock with a Strong Buy rating, eleven have given a Buy rating and seven have given a Hold rating to the stock. Based on data from MarketBeat.com, Merck & Co., Inc. has an average rating of “Moderate Buy” and a consensus price target of $128.18.

Read Our Latest Report on Merck & Co., Inc.

Merck & Co., Inc. Price Performance

NYSE:MRK opened at $114.04 on Friday. The company has a quick ratio of 1.06, a current ratio of 1.30 and a debt-to-equity ratio of 1.02. The stock’s 50 day moving average price is $115.94 and its two-hundred day moving average price is $113.60. The firm has a market capitalization of $281.65 billion, a price-to-earnings ratio of 32.12, a P/E/G ratio of 2.56 and a beta of 0.21. Merck & Co., Inc. has a 12-month low of $76.66 and a 12-month high of $125.14.

Merck & Co., Inc. (NYSE:MRK – Get Free Report) last released its quarterly earnings data on Thursday, April 30th. The company reported ($1.28) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.47) by $0.19. Merck & Co., Inc. had a return on equity of 27.55% and a net margin of 13.59%.The company had revenue of $16.29 billion during the quarter, compared to analysts’ expectations of $15.85 billion. During the same period last year, the firm posted $2.22 earnings per share. The business’s revenue was up 4.9% on a year-over-year basis. Merck & Co., Inc. has set its FY 2026 guidance at 5.040-5.160 EPS. On average, analysts anticipate that Merck & Co., Inc. will post 5.17 earnings per share for the current year.

Merck & Co., Inc. Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, July 8th. Shareholders of record on Monday, June 15th will be issued a dividend of $0.85 per share. The ex-dividend date of this dividend is Monday, June 15th. This represents a $3.40 annualized dividend and a yield of 3.0%. Merck & Co., Inc.’s dividend payout ratio (DPR) is currently 95.77%.

About Merck & Co., Inc.

(Free Report)

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.